## Opioid Maintenance in Pregnancy **Key Point:** Continuation of buprenorphine maintenance therapy is the standard of care in pregnant women with opioid use disorder. Abrupt discontinuation poses greater risks to both mother and fetus than continued treatment. ### Rationale for Continuing Buprenorphine 1. **Maternal safety:** Abrupt cessation triggers relapse in >70% of patients, leading to return to illicit opioid use, which carries risks of: - Overdose and maternal death - Intrauterine drug exposure and fetal harm - Maternal malnutrition and poor prenatal care - Obstetric complications (preterm labor, placental abruption) 2. **Fetal safety:** Buprenorphine has a favorable safety profile in pregnancy: - **Pregnancy Category C** (older classification) / **Category C** (FDA); no teratogenic effects documented in large cohort studies - **Partial agonist properties** reduce risk of fetal opioid dependence compared to full agonists - Stable maternal opioid levels prevent fetal withdrawal, which increases miscarriage and preterm labor risk - Neonatal opioid withdrawal syndrome (NOWS) occurs in ~60–80% of exposed infants but is mild and manageable with supportive care 3. **Evidence base:** Multiple guidelines (ACOG, SAMHSA, WHO) recommend **continuation of buprenorphine** or methadone throughout pregnancy as the gold standard. ### Neonatal Opioid Withdrawal Syndrome (NOWS) **High-Yield:** NOWS is **not prevented by dose reduction**; it is determined by cumulative fetal opioid exposure and maternal opioid dependence, not by dose. Reducing buprenorphine to subtherapeutic levels (e.g., 2 mg) risks maternal relapse without reducing NOWS severity. NOWS symptoms typically appear 24–72 hours after birth and include: - Irritability, high-pitched cry, tremor - Poor feeding, diarrhea, vomiting - Seizures (rare, <1%) Management is **supportive** (swaddling, frequent feeding, rooming-in) with pharmacotherapy (morphine or methadone) reserved for severe cases. ### Comparison of Opioid Maintenance Agents in Pregnancy | Agent | Pregnancy Safety | NOWS Risk | Maternal Relapse Risk | Dosing Frequency | Recommendation | | --- | --- | --- | --- | --- | --- | | **Buprenorphine** | Category C; no teratogenicity | 60–80% (mild) | Low (partial agonist) | Daily or every 48–72 h | **First-line** | | **Methadone** | Category C; established safety | 80–90% (more severe) | Low (full agonist) | Daily | **Alternative** | | **Naltrexone** | Category C; limited data | None | **Very high (>80%)** | Daily | **Contraindicated** | | **Abrupt cessation** | **Unsafe** | Variable (relapse-dependent) | **>70% relapse rate** | — | **Contraindicated** | **Clinical Pearl:** Buprenorphine is increasingly preferred over methadone in pregnancy because it has a **lower risk of NOWS severity** and **lower abuse potential**, making it easier for pregnant women to remain engaged in treatment. ### Dose Adjustment in Pregnancy Dose adjustments are **not routinely recommended** based solely on pregnancy status. However: - Some women require **dose increases** in the second and third trimesters due to increased volume of distribution and hepatic metabolism - Dose should be adjusted based on **maternal withdrawal symptoms and cravings**, not fetal considerations - **Therapeutic drug monitoring** (plasma buprenorphine levels) may guide dosing in difficult cases **Mnemonic:** **CONTINUE** = **C**ontinue opioid maintenance, **O**oid safety is paramount, **N**o abrupt cessation, **T**reatment prevents relapse, **I**nfant outcomes improve with maternal stability, **N**eonatal withdrawal is manageable, **U**nderstanding reduces maternal anxiety, **E**vidence supports continuation.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.